U.S. Regulators Approve Cymbalta® For Treatment Of Generalised Anxiety Disorder
The U.S. Food and Drug Administration (FDA) has approved the antidepressant Cymbalta® (duloxetine HCl) for the treatment of generalised anxiety disorder (GAD), Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim announced today.
No comments:
Post a Comment